Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17400554 
Nguyen C, et al. (2007) Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5. J Biol Chem 282, 16511-20 17400554
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S6-p - PPP1R1A (rat)
Orthologous residues
PPP1R1A (human): S6‑p, PPP1R1A (mouse): S6‑p, PPP1R1A (rat): S6‑p, PPP1R1A (rabbit): S6‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', 'brain, hippocampus', 'brain, striatum', PC-12 (chromaffin)
 Cellular systems studied:  cell lines, tissue
 Species studied:  mouse, rat
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK5 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK5 (mouse) pharmacological inhibitor of upstream enzyme
PHOSPHATASE PPP2R5A (mouse) pharmacological inhibitor of upstream enzyme
PHOSPHATASE PPP1CA (mouse) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine decrease
butyrolactone decrease
U0126 no change compared to control
indolinone A decrease
indolinone B no change compared to control
fostriecin increase
neurabin increase
cyclosporin A no change compared to control
okadaic acid increase
NMDA decrease
forskolin increase

T35-p - PPP1R1A (rat)
Orthologous residues
PPP1R1A (human): T35‑p, PPP1R1A (mouse): T35‑p, PPP1R1A (rat): T35‑p, PPP1R1A (rabbit): T35‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  'brain, striatum'
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NMDA decrease

S67-p - PPP1R1A (rat)
Orthologous residues
PPP1R1A (human): S67‑p, PPP1R1A (mouse): S67‑p, PPP1R1A (rat): S67‑p, PPP1R1A (rabbit): S67‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', kidney
 Cellular systems studied:  tissue
 Species studied:  mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK5 (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.